Journal
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Volume 16, Issue -, Pages 12-17Publisher
WILEY
DOI: 10.1111/ajco.13314
Keywords
adjuvant; axitinib; renal cell carcinoma; S-TRAC; sunitinib
Categories
Ask authors/readers for more resources
Adjuvant treatment with VEGFR tyrosine kinase inhibitor in renal cell carcinoma after nephrectomy has been reported through four clinical trials: S-TRAC, ASSURE, PROTECT and ATLAS. Only S-TRAC has been significantly positive on primary endpoint DFS under sunitinib compared to placebo, whereas ASSURE, PROTECT and ATLAS did not show any gain under sunitinib, sorafenib, pazopanib or axitinib, respectively. Nevertheless, there are arguments for a trend for the impact of anti-angiogenic therapy on outcome of patients with high-risk renal cell carcinoma cancer following nephrectomy, allowing for a fair discussion with patients to decide for or against an adjuvant treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available